Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
Fifty years after F. Macfarlane Burnet published his seminal paper on the clonal-selection theory of antibody diversity, six key scientists provide their thoughts and opinions on how this theory was received and how it has helped to shape immunology as we know it today.
In this Viewpoint article, four leading researchers provide their view on the prospect of using tolerogenic cells as an immunotherapy in humans and highlight some of the hurdles that must be addressed for this type of treatment to become a viable therapeutic approach.
